-
Dabigatran Workflows for Thrombin Assays
2026-08-23
Build reproducible thrombin inhibition assays with Dabigatran, from concentration selection and plasma handling to PT, aPTT, and TT interpretation. This practical guide also shows how findings from berberrubine metabolomics research can sharpen assay selection without confusing pathway modulation with direct thrombin blockade.
-
BCAA Rheostat Restores Replicative HSC Fitness
2026-08-22
Bartram and colleagues show that accumulated HSC divisions produce metabolic, transcriptional, and functional drift rather than simply reducing stem-cell output. Their work identifies a shift in branched-chain amino acid use and demonstrates that replacing a BCAA transamination product can slow cell-cycle progression and restore more balanced hematopoietic regeneration.
-
EPZ-6438: Practical EZH2 Inhibitor Workflows
2026-08-21
EPZ-6438 gives researchers a selective way to connect EZH2 catalytic inhibition with H3K27me3 loss, transcriptional change, and cancer-cell phenotypes. This guide translates its use into reproducible dose–time studies, combination assays, malignant rhabdoid tumor models, lymphoma workflows, and melanoma resistance experiments.
-
Gαs-Selective G Protein Antagonists: NF 449
2026-08-20
The 1998 PNAS study identified NF 449 and NF503 as suramin analogues that preferentially inhibit Gαs activation and receptor coupling while sparing representative Gi/Go- and Gq-linked pathways. Its integrated nucleotide-binding, adenylyl cyclase, and receptor-coupling experiments established a framework for subtype-selective G protein inhibition and clarified why NF 449 should not be conflated automatically with later P2X1 or platelet applications.
-
Dinaciclib-VHL Synthetic Lethality in CC-RCC
2026-08-20
The reference study identifies a selective vulnerability in clear cell renal cell carcinoma: VHL-deficient tumors are unusually sensitive to the multi-cyclin-dependent kinase inhibitor Dinaciclib. Combining cell-based, molecular, and orthotopic patient-derived xenograft experiments, the authors show that Dinaciclib suppresses tumor growth while affecting both CD105-positive cancer stem cells and CD105-negative tumor cells.
-
EdU Imaging Kits (Cy5) for S-Phase Studies
2026-08-19
EdU Imaging Kits (Cy5) provide a morphology-preserving way to quantify DNA synthesis in adherent cells, tissue-derived cultures, and flow-cytometry samples. Their Cy5 click-chemistry readout is especially useful when proliferation must be separated from migration, apoptosis, or cell-cycle disruption in wound-healing and pharmacodynamic models.
-
Canagliflozin as an mTOR Assay Boundary Probe
2026-08-19
Canagliflozin hemihydrate is best known for renal glucose reabsorption inhibition, but a 2025 yeast study gives it a second research value: a negative-control boundary probe for mTOR inhibitor discovery. This article explains how to use that finding to design, interpret, and troubleshoot glucose metabolism research assays.
-
Cell lysis buffer for WB and IP in CAF Studies
2026-08-18
Translate CAF-driven chemoresistance biology into cleaner Western blot, co-IP, and signaling workflows with a non-denaturing extraction strategy. This guide shows how to use inhibitor-protected lysates to examine the ANGPTL4–IQGAP1 axis while preserving protein abundance, phosphorylation, and native complexes.
-
Ceftolozane Sulfate: From Target to Translation
2026-08-18
A translational framework for using Ceftolozane sulfate in mechanism-driven susceptibility testing, PK/PD studies, infection models, and resistance-aware development programs.
-
Cholesterol Hinders LNP Intracellular Trafficking
2026-08-17
A 2025 study developed a high-throughput imaging platform to track nucleic acid-loaded lipid nanoparticles (LNPs) through intracellular compartments. Its findings indicate that excess cholesterol promotes aggregation of LNP-containing peripheral early endosomes, restricting endolysosomal progression and reducing access to compartments associated with cargo release.
-
HyperScribe T7 High Yield Cy5 RNA Labeling Kit
2026-08-17
The HyperScribe T7 High Yield Cy5 RNA Labeling Kit is a Cy5 RNA labeling kit for tunable fluorescent RNA probe synthesis by T7-driven in vitro transcription. Its Cy5-UTP substitution strategy supports probe preparation for in situ hybridization and Northern blot hybridization while requiring empirical optimization of labeling versus transcription yield.
-
IWP-L6: Practical Porcupine Inhibition Workflows
2026-08-16
IWP-L6 provides upstream control of Wnt ligand maturation, making it useful for separating endogenous Wnt production from downstream pathway effects. This guide translates its sub-nanomolar potency into practical workflows for signaling, metabolism, organ culture, and regeneration assays.
-
Protoporphyrin IX in Ferroptosis Workflows
2026-08-15
Use Protoporphyrin IX as a carefully controlled probe of heme formation, iron handling, and light-triggered oxidative injury. This workflow connects photodynamic assays with the METTL16–SENP3–LTF ferroptosis axis while separating direct evidence from practical assay extensions.
-
Anlotinib and VEGFR2-Driven Tumor Angiogenesis
2026-08-14
The 2018 Cancer Science study established anlotinib as a highly potent, relatively selective VEGFR2 inhibitor with activity spanning kinase assays, endothelial models, aortic explants, and tumor-bearing mice. Its layered design links endothelial signaling blockade to reduced angiogenesis and stronger oral antitumor activity than sunitinib in several preclinical settings, while also clarifying that direct tumor-cell inhibition requires substantially higher concentrations.
-
GW 6471: Reframing PPARα in Translational Research
2026-08-14
GW 6471 provides a mechanistically defined way to interrogate PPARα-dependent transcription, connecting receptor biology with lipid homeostasis, hepatotoxicity, and metabolic disease research. This article translates findings from a PFHxS-exposed zebrafish model into a disciplined pharmacology strategy, while distinguishing evidence-supported conclusions from future translational hypotheses.